News & Updates

pCOCR-CADTH Releases Positive Initial Reccomendation for Tagrisso

More good news for NSCLC patients!  Both lung cancer drugs Tagrisso (osimertinib) and Zykadia (ceritinib) received positive initial recommendations from pCODR-CADTH.

Major Step Forward in Accessing New Life-Extending Medication

Major Step Forward in Accessing New Life-Extending Medication for Advanced Metastatic Lung, Melanoma and Kidney Cancer Patients.

Canadian lung, melanoma and kidney cancer patients are one step closer to gaining access to immunotherapy after pCPA negotiations have concluded. Provinces and Territories are encouraged to list quickly.
 

CCO is Introducing a Lung Cancer Screening Pilot

Cancer Care Ontario is introducing a lung cancer screening pilot program for people at high risk in April 2017.

Faces of Lung Cancer Report 2016

Ottawa, ON, November 1, 2016 – The third annual Faces of Lung Cancer Report is released and inspires a message of hope as Lung Cancer Canada charts a path forward to improve the dire situation for Canadian patients. In 2016, multiple sources clearly demonstrated the level of progress that still needs to be made in Canada, specifically when it comes to lung cancer research, rising rates of the disease in women and the consequences of lengthy approval and coverage timelines. [Read the News Release]

Stakeholder Briefing

New Research Shows Canadian Lung Cancer Patients Are Disadvantaged Compared to Their US Peers and Shocking Trends Among Women

Canadian Cancer Statistics 2016

The Canadian Cancer Society has released the Canadian Cancer Statistics 2016.  Lung cancer remains deadliest cancer for CDN men & women the lowest 5-year survival (17%) of any major cancer.

Scotiabank Toronto Waterfront Marathon

Thank you to everyone who participated in the Scotiabank Toronto Waterfront Marathon in support of lung cancer!

Lung Cancer is not Just a Smoker's Disease!

As a healthy, active non-smoker, Jessica Steinberg was shocked by her diagnosis.  Jessica had to face a life-threatening cancer diagnosis while juggling single parenthood.
 

pCODR Recommends Nivolumab (Opdivo)

pCODR recommends nivolumab (Opdivo) for funding in its Final Recommendation for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.

This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer.

LCC on Instagram and LinkedIn

Lung Cancer Canada has added two new social media profiles.
Follow us on LinkedIn and Instagram!

Displaying results 31-40 (of 62)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|